CombiMatrix's Q2 Revenues Rise 29 Percent; Shares Drop on Legal Expenses | GenomeWeb

NEW YORK (GenomeWeb) – CombiMatrix today reported that its second quarter revenues rose 29 percent year over year, driven by 60 percent growth in prenatal microarray testing volumes.

For the three months ended June 30, the Irvine, Calif.-based molecular diagnostics company saw revenues climb to $1.9 million from $1.5 million in the second quarter of 2013. Its revenues were in line with the consensus Wall Street estimate.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.